Treatment
Semaglutide clinical trials
We’re tracking 144 recruiting studies that include Semaglutide, each written for real people, not researchers, below.
Recruiting studies
- NCT05424003RecruitingPhase 2
Semaglutide to prevent weight gain after liver transplant
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
Richmond, VirginiaAges 18–75 - NCT05501483Recruiting
Study how fat differences may relate to type 2 diabetes
This study looks at differences in body fat to understand why some people develop type 2 diabetes. You may be asked for blood tests and health information to see if your diabetes risk and body fat patterns are linked.
StockholmAges 30–70 - NCT05586802RecruitingPhase 3
Balancing sex hormones to improve metabolism and fertility in Klinefelter
This study tests whether adjusting sex-hormone levels can improve body metabolism and reproductive hormone balance in people with Klinefelter syndrome. Depending on the design, you may be looking at fertility preservation and/or metabolic health.
LausanneAges 16–65 - NCT05938712RecruitingPhase 2
Kidney transplant trial using two diabetes medicines safely
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Toronto, OntarioAges 18 years+ - NCT06082063RecruitingPhase 3
Reducing heart disease risk in type 1 diabetes
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
CopenhagenAges 40–90 - NCT06184633RecruitingPhase 4
Weight control in atrial fibrillation study
This study tests if a weight management program helps people with a new type of irregular heartbeat (atrial fibrillation) and obesity. It aims to see if losing weight can improve heart rhythm and reduce the need for further treatment.
Arnhem, GelderlandAges 18 years+ - NCT07653412Recruiting
Genetic test for predicting weight loss drug response
This trial looks at whether your genes can predict how well you will respond to weight loss medications like semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro). It may help doctors choose the right drug for you based on your DNA.
AthensAges 18 years+ - NCT07091500Recruiting
Exercise and a weight-loss drug for people with obesity
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
St Louis, MissouriAges 50–75 - NCT06338553RecruitingEarly Phase 1
GLP-1 drug for early type 1 diabetes
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Nashville, TennesseeAges 12–50 - NCT06410352RecruitingPhase 4
Weight loss methods for longer life with metabolic syndrome
This trial tests weight loss methods in people with type 2 diabetes, high blood pressure, and excess weight. It aims to see if losing 15-20% of body weight can help people live longer and healthier.
Astana, AstanaAges 35–65 - NCT06411210RecruitingPhase 2
Weight loss medication for young adults with type 1 diabetes
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
New Haven, ConnecticutAges 18–30 - NCT06423599RecruitingPhase 2/Phase 3
Weight Loss for Obesity and Heart Failure
This study tests whether weight loss from a medication can improve how you feel, move, and how well your heart works. It's for people who have both obesity and heart failure with reduced pumping strength.
CopenhagenAges 18 years+ - NCT06461377RecruitingPhase 4
GLP-1RA for heart nerve damage in type 2 diabetes
This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.
Nanjing, JiangsuAges 18–70 - NCT06613854RecruitingPhase 4
Early combination therapy for type 2 diabetes
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
LjubljanaAges 18–70 - NCT06706284RecruitingPhase 4
GLP-1 agonist for diabetes after spinal cord injury
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
San Antonio, TexasAges 18–70 - NCT06716216RecruitingPhase 3
Study of BGM0504 for people with type 2 diabetes
This trial tests an investigational drug called BGM0504 in people with type 2 diabetes who are already taking metformin or metformin plus another diabetes medicine. It aims to see if the drug can help lower blood sugar levels.
Beijing, Beijing MunicipalityAges 18–75 - NCT06717698RecruitingPhase 2
Testing a new medicine for kidney damage in chronic kidney disease
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
San Dimas, CaliforniaAges 18 years+ - NCT06836284Recruiting
Extra support for teens in obesity treatment
This study is for teens aged 12–17 who are already being offered weight-loss medications. It adds extra support to see if that helps them do better with treatment.
LinköpingAges 12–17 - NCT06897475RecruitingPhase 2
Study of LY3457263 for type 2 diabetes on semaglutide or tirzepatide
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
Phoenix, ArizonaAges 18–75 - NCT06908694RecruitingPhase 4
GLP-1 drugs for weight management in prostate cancer
This trial tests if a GLP-1 receptor agonist (a type of diabetes drug that helps with weight loss) can help men with prostate cancer who are on hormone therapy (ADT) and have a high body mass index (BMI). It aims to see if it improves their health and outcomes.
Hamilton, OntarioAges 18 years+ - NCT06989177Recruiting
Can a probiotic help with body weight?
This trial tests whether taking a probiotic (a good bacteria supplement) can help with body weight. It is for healthy adults, and also for overweight or obese people who have certain weight-related health issues.
Hangzhou, ZhejiangAges 20–50 - NCT06989203Recruiting
Protein supplement study for body weight
This trial tests how protein supplements affect body weight in people who are either normal weight or overweight. The goal is to see if adding protein helps with weight management.
Hangzhou, ZhejiangAges 20–50 - NCT07017270RecruitingPhase 4
GLP-1 drugs for people with diabetes on dialysis
This study tests if a type 2 diabetes medication called a GLP-1 receptor agonist (like Ozempic) is safe and effective for people on dialysis. It may help manage blood sugar and improve health outcomes for those with kidney failure.
Toronto, OntarioAges 18 years+ - NCT07064486RecruitingPhase 3
BGM0504 for type 2 diabetes in Indonesia
This study tests a new medicine called BGM0504 for people with type 2 diabetes who are already taking metformin. It may help improve blood sugar control and weight.
Depok, West JavaAges 18–75
Common questions
- Are there clinical trials studying Semaglutide?
- Yes. Clin2 currently lists 144 recruiting studies that include Semaglutide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Semaglutide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Semaglutide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Semaglutide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.